Group 1 - The company has expanded its partnership agreement with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL PF in Singapore [1] - The company has established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize BRIMOCHOL PF in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights for BRIMOCHOL PF in their respective markets, marking them as the seventh and eighth commercialization partners for the product [1] Group 2 - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia, acquired as a core asset through a partnership with Tenpoint Therapeutics, Ltd. [2] - Tenpoint is a global biotechnology company developing breakthrough therapies to restore vision in aging eyes [2] - The FDA has accepted the new drug application for BRIMOCHOL PF, with a review deadline set for January 28, 2026 [2]
兆科眼科-B透过与AFT及千寿建立伙伴关系，推动用于治疗老花眼的BRIMOCHOL PF于新加坡及越南的商业化进程